

**Agenda:** To review and evaluate grant applications.

**Place:** Video Assisted Meeting.

**Contact Person:** Leonid V. Tsap, Ph.D., Scientific Review Officer, Extramural Programs, National Library of Medicine, NIH, 6705 Rockledge Drive, Suite 500, Bethesda, MD 20892-7968, 301-827-7077, [tsapl@mail.nih.gov](mailto:tsapl@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: November 2, 2020.

**Ronald J. Livingston, Jr.,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-24669 Filed 11-5-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Aging Special Emphasis Panel; Clinical trials for COVID 19 management in older individuals.

**Date:** December 11, 2020.

**Time:** 10:00 a.m. to 1:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

**Contact Person:** Maurizio Grimaldi, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496-9374, [grimaldim2@mail.nih.gov](mailto:grimaldim2@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: November 2, 2020.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-24615 Filed 11-5-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive Patent License: Treatment of Hermansky-Pudlak Syndrome and Idiopathic Pulmonary Fibrosis

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Heart, Lung and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), both of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive patent license to Inversago Pharma Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the National Human Genome Research Institute's Technology Transfer Office on or before November 23, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Anna Solowiej, Ph.D., J.D., Senior Licensing and Patenting Manager, NHGRI Technology Transfer Office; Telephone (301) 435-7791; Email: [anna.solowiej@nih.gov](mailto:anna.solowiej@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma Inc.:

NIH ref No.	Patent No. or application No.	Issue date	Filing date	Title
E-282-2012-0-US-01 .....	61/725,949 .....	.....	November 13, 2012 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-PCT-02 .....	PCT/US2013/069686 .....	.....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-03 .....	9,765,031 .....	September 19, 2017 .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CA-04 .....	2889697 .....	.....	April 27, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-EP-05 .....	13802153.0 .....	TBD .....	June 01, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CH-12 .....	13802153.0 .....	TBD .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-DE-13 .....	13802153.0 .....	TBD .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-FR-14 .....	13802153.0 .....	TBD .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-GB-15 .....	13802153.0 .....	TBD .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IE-16 .....	13802153.0 .....	TBD .....	November 12, 2013 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IN-06 .....	3733/DELNP/2015 .....	.....	May 1, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-JP-07 .....	6272626 .....	January 12, 2018 .....	May 11, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CN-08 .....	ZL201380069389.9 .....	August 20, 2019 .....	July 3, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-09 .....	10,683,270 .....	June 16, 2020 .....	August 10, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-10 .....	15/674,333 .....	TBD (application allowed) .....	August 10, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-11 .....	16/870,093 .....	.....	May 8, 2020 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-01 .....	62/171,179 .....	.....	June 4, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-PCT-02 .....	PCT/US2016/035291 .....	.....	June 1, 2016 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-EP-05 .....	16/28547.7 .....	.....	June 1, 2016 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-08 .....	15/579,123 .....	.....	December 1, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-09 .....	16/438,850 .....	.....	June 12, 2019 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-US-01 .....	15/061,829 .....	.....	March 4, 2016 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-PCT-02 .....	PCT/US2017/020250 .....	.....	March 1, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-CN-03 .....	2017800118698 .....	.....	March 1, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-282-2012-2-EP-04 .....	17711443.6 .....	.....	March 1, 2017 .....	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-01 .....	61/991,333 .....	.....	May 9, 2014 .....	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-PCT-02 .....	PCT/US2015/029946 .....	.....	May 8, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-AU-03 .....	2015255765 .....	.....	November 7, 2016 .....	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CA-04 .....	2948349 .....	.....	May 8, 2015 .....	Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CN-05 .....	201580028788.X .....	February 7, 2020 .....	May 8, 2015 .....	Cannabinoid Receptor Mediating Compounds.